Merck KGaA/Pfizer's Bavencio Set To Enter Europe's Crowded I-O Market

 
• By Kevin Grogan

The highly-competitive PD-1 field in Europe is very likely to have a new player as Bavencio gets a CHMP recommendation for Merkel cell carcinoma, but the success of Merck KGaA and Pfizer's checkpoint inhibitor will be gauged on how it competes with the competition already on the market in wider, more valuable indications.

Running
Playing catch-up: Bavencio should soon join the I-O race in Europe • Source: Shutterstock

More from Anticancer

More from Therapy Areas